更新于：2024-05-01
Dextrose
葡萄糖
更新于：2024-05-01
概要
基本信息
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1971-01-25), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看首次获批时间轴
关联
213
项与 葡萄糖 相关的临床试验Prevention of neonatal hypoglycemias with oral dextrose gel among high-risk neonates admitted in Tertiary care centre - NIL
The Relationship of Preoperative Intravenous Dextrose Infusion to Postoperative Nausea and Vomiting in Gynecological Laparoscopic and Hysteroscopic Surgeries: A Randomized Control Trial
Effectiveness of 25% dextrose versus expressed breast milk on the vital parameters, pain, and comfort level during heel prick among neonates in selected hospitals of Lumbini Province, Nepal - NIL
100 项与 葡萄糖 相关的临床结果
登录后查看更多信息
100 项与 葡萄糖 相关的转化医学
登录后查看更多信息
100 项与 葡萄糖 相关的专利（医药）
登录后查看更多信息
5,014
项与 葡萄糖 相关的文献（医药）2024-02-22International immunopharmacology
High glucose intake exacerbates experimental autoimmune prostatitis through mitochondrial reactive oxygen species-dependent TGF-β activation-mediated Th17 differentiation.
Article
作者: Di Niu ; Shao-Yu Yue ; Xu Wang ; Wei-Yi Li ; Li Zhang ; He-Xi Du ; Chao-Zhao Liang
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common inflammatory immune disease of the urogenital system. High glucose intake is considered to be a potential promoter of autoimmune diseases. However, the influence of high glucose intake on CP/CPPS is unknown. This research aimed to explore the influences of high glucose intake on experimental autoimmune prostatitis (EAP), a valid animal model of CP/CPPS, and the underlying mechanism. NOD mice received 20% glucose water or normal water treatment during EAP induction. EAP severity and Th17 cell responses were evaluated. Then, we explored the effects of an IL-17A neutralizing antibody, an inhibitor of TGF-β, the reactive oxygen species (ROS) inhibitor NAC, and the mitochondrial ROS (mtROS) antioxidant MitoQ on glucose-fed EAP mice. The results demonstrated that high glucose intake aggravated EAP severity and promoted Th17 cell generation, which could be ameliorated by the neutralization of IL-17A. In vitro experiments showed that high dextrose concentrations promoted Th17 cell differentiation through mtROS-dependent TGF-β activation. Treatment with TGF-β blockade, NAC, or MitoQ suppressed Th17 cell generation both in vivo and in vitro, resulting in the amelioration of EAP manifestations caused by high glucose intake. This study revealed that high glucose intake exacerbates EAP through mtROS-dependent TGF-β activation-mediated Th17 differentiation. Our results may provide insights into the molecular mechanisms underlying the detrimental effects of an environmental factor, such as high glucose intake, on CP/CPPS.
2024-02-05Nutrients
Carbohydrate Oral Rinsing, Cycling Performance and Individual Complex Carbohydrate Taste Sensitivity.
Article
作者: Claudia Hartley ; Amelia Carr ; Spencer S H Roberts ; Wender L P Bredie ; Russell S J Keast
The aim of this pilot study was to determine the effect of individual complex carbohydrate taste sensitivity on cycling performance with complex carbohydrate oral rinsing. Ten male participants completed five cycling time trials in a fasted state with a seven-day washout period between each trial. Participants completed a fixed amount of work (738.45 ± 150.74 kJ) as fast as possible on a cycle ergometer while rinsing with an oral rinse for 10 s every 12.5% of the trial. An oral rinse (maltodextrin, oligofructose, glucose, sucralose or water control) was given per visit in a randomised, crossover, blinded design. Afterwards, participants had their taste assessed with three stimuli, complex carbohydrate (maltodextrin), sweet (glucose) and sour (citric acid), using taste assessment protocol to determine individual taste sensitivity status. Participants were subsequently grouped according to their complex carbohydrate taste sensitivity and complex carbohydrate taste intensity. There were no significant effects of the oral rinses on cycling performance time (p = 0.173). Participants who did not have improvements in exercise performance with the maltodextrin rinse experienced a stronger taste intensity with complex carbohydrate stimuli at baseline (p = 0.047) and overall (p = 0.047) than those who did have improvements in performance. Overall, a carbohydrate oral rinse was ineffective in significantly improving cycling performance in comparison with a water control. However, when participants were grouped according to complex carbohydrate taste intensity, differences in exercise performance suggest that individual sensitivity status to complex carbohydrates could impact the efficacy of a carbohydrate-based oral rinse.
2024-02-04BJOG : an international journal of obstetrics and gynaecology
The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).
Article
作者: Catherine Nelson-Piercy ; Caitlin Dean ; Manjeet Shehmar ; Roger Gadsby ; Margaret O'Hara ; Kenneth Hodson ; Melanie Nana ; Royal College of Obstetricians and Gynaecologists
An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) and HyperEmesis Level Prediction (HELP) tools can be used to classify the severity of NVP and HG. [Grade C] Ketonuria is not an indicator of dehydration and should not be used to assess severity. [Grade A] There are safety and efficacy data for first line antiemetics such as anti (H1) histamines, phenothiazines and doxylamine/pyridoxine (Xonvea®) and they should be prescribed initially when required for NVP and HG (Appendix III). [Grade A] There is evidence that ondansetron is safe and effective. Its use as a second line antiemetic should not be discouraged if first line antiemetics are ineffective. Women can be reassured regarding a very small increase in the absolute risk of orofacial clefting with ondansetron use in the first trimester, which should be balanced with the risks of poorly managed HG. [Grade B] Metoclopramide is safe and effective and can be used alone or in combination with other antiemetics. [Grade B] Because of the risk of extrapyramidal effects metoclopramide should be used as second-line therapy. Intravenous doses should be administered by slow bolus injection over at least 3 minutes to help minimise these. [Grade C] Women should be asked about previous adverse reactions to antiemetic therapies. If adverse reactions occur, there should be prompt cessation of the medications. [GPP] Normal saline (0.9% NaCl) with additional potassium chloride in each bag, with administration guided by daily monitoring of electrolytes, is the most appropriate intravenous hydration. [Grade C] Combinations of different drugs should be used in women who do not respond to a single antiemetic. Suggested antiemetics for UK use are given in Appendix III. [GPP] Thiamine supplementation (either oral 100 mg tds or intravenous as part of vitamin B complex (Pabrinex®)) should be given to all women admitted with vomiting, or severely reduced dietary intake, especially before administration of dextrose or parenteral nutrition. [Grade D] All therapeutic measures should have been tried before considering termination of pregnancy. [Grade C].
100 项与 葡萄糖 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 水电解质代谢紊乱 | 批准上市 | 美国 更多 | |
| - | 申请上市 | 中国 更多 | |
| 糖尿病前期 | 临床2期 | 美国 更多 | |
| 葡萄糖耐受不良 | 临床2期 | 美国 更多 | |
| 肥胖 | 临床2期 | 波多黎各 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | glucose | (壓獵蓋築餘製觸夢鬱遞) = 網窪蓋衊鹽餘夢鹽膚獵 齋築鹹蓋築鹽壓簾艱鹹 (夢餘窪願簾製醖壓壓醖, 832.5) | - | 2014-04-01 | |
glucose | (壓獵蓋築餘製觸夢鬱遞) = 鏇遞醖壓製鹹獵夢網壓 齋築鹹蓋築鹽壓簾艱鹹 (夢餘窪願簾製醖壓壓醖, 432.05) | ||||||
N/A | 10 | 選鏇顧襯獵積餘膚夢艱(醖衊膚積鏇遞鬱選願製) = 衊鏇襯觸鏇繭襯繭網餘 壓衊積齋願餘鹹繭衊鏇 (繭願憲願窪範願製憲餘 ) 更多 | - | 2021-06-01 | |||
临床2/3期 | 32 | (繭夢膚鏇鬱範襯窪簾鑰) = 鬱觸醖積廠積獵窪夢壓 壓獵構衊餘夢糧齋觸鹽 (壓顧餘餘製積餘觸鑰膚 ) | 积极 | 2018-12-01 | |||
N/A | 35 | 膚範鏇範醖構鬱淵餘築(糧淵鬱獵糧醖鹽鑰選選) = 餘壓選壓蓋窪鑰壓獵壓 餘願廠遞齋積範積壓鑰 (餘範積選膚積範夢獵鹹 ) 更多 | - | 2016-12-06 | |||
0.9% Saline | 膚範鏇範醖構鬱淵餘築(糧淵鬱獵糧醖鹽鑰選選) = 夢網積淵網選糧築願窪 餘願廠遞齋積範積壓鑰 (餘範積選膚積範夢獵鹹 ) 更多 | ||||||
N/A | - | 襯憲蓋鹽襯鑰衊鬱廠齋(積鬱糧選衊網蓋廠簾糧) = 鹹衊襯夢製簾構窪繭膚 鹽鹹願構網壓獵鏇築衊 (襯齋願觸選觸夢積鹹觸 ) | - | 2023-08-27 | |||
N/A | - | 43 | 蓋醖餘鬱選窪壓製範築(獵鑰簾廠網鬱齋遞鑰繭) = 醖壓艱鬱廠顧蓋夢蓋製 鏇築糧廠衊蓋願遞鹽獵 (鑰夢窪衊顧膚製淵衊觸 ) | - | 2018-05-08 | ||
襯製壓齋構製醖觸簾積(獵蓋壓顧繭網餘網齋顧) = 願憲製艱獵顧窪簾鬱繭 醖膚繭衊鑰簾構蓋窪獵 (顧齋蓋蓋窪餘憲鹽簾鬱 ) 更多 | |||||||
N/A | 12 | 夢齋繭廠餘鑰醖鬱餘鑰(網廠範鑰築願衊淵壓選) = 廠構艱淵醖窪繭廠齋鏇 積構壓選遞憲糧蓋鬱鏇 (簾積簾艱簾廠鑰觸鹹簾 ) | - | 2020-06-01 | |||
(No administration of drugs) | 夢齋繭廠餘鑰醖鬱餘鑰(網廠範鑰築願衊淵壓選) = 齋夢膚廠鹽顧範鑰願鹽 積構壓選遞憲糧蓋鬱鏇 (簾積簾艱簾廠鑰觸鹹簾 ) | ||||||
N/A | 28 | (鑰製鑰衊範糧鑰壓築範) = 鬱網齋鹹構願網艱遞廠 製鏇糧糧簾糧膚糧簾窪 (窪壓簾鏇衊憲構簾齋夢, 0.09 ~ 0.42) 更多 | - | 2013-06-01 | |||
N/A | - | Diazoxide 15mg PO TID | (糧衊夢積窪範鏇範積淵) = 鏇糧糧夢齋艱繭鏇艱遞 遞積膚繭衊憲選廠糧簾 (鹽夢艱夢觸選廠鑰餘顧 ) 更多 | - | 2018-09-27 | ||
(淵夢鏇壓膚繭齋膚顧積) = 選餘廠艱艱鏇餘窪鏇鹽 鏇餘醖淵願製觸餘繭繭 (製遞餘蓋鹹製選鹹壓鏇 ) | |||||||
N/A | 60 | (Patients with LCHADD) | 積醖醖窪獵願齋鏇鹹鹹(獵膚廠觸餘憲簾壓衊衊) = 遞顧觸鹹醖簾鏇觸網構 構鬱壓鬱積餘選齋製廠 (鏇鏇鹹簾積積艱憲願鹽 ) | - | 2019-09-01 | ||
(Healthy persons) | 積醖醖窪獵願齋鏇鹹鹹(獵膚廠觸餘憲簾壓衊衊) = 膚衊顧獵齋襯鏇繭壓艱 構鬱壓鬱積餘選齋製廠 (鏇鏇鹹簾積積艱憲願鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用